Compare Medpace Holdings Inc (MEDP) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Prospect Capital Corporation — how do they compare? Medpace Holdings Inc trades at $601.68 (market cap $16.90B), while Prospect Capital Corporation trades at $2.29 (market cap $1.14B). The key difference: Medpace Holdings Inc is far larger — about 14.8× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 21.93% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | PSEC | |
|---|---|---|
Market Cap | $16.90B | $1.14B |
Sector | Technology | Financials |
52-Week High | $620.59 | $3.05 |
52-Week Low | $393.42 | $2.11 |
Enterprise Value | $16.52B | — |
Dividend Yield | — | 21.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Prospect Capital Corporation (PSEC) trades at $2.285, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows mixed fundamentals with a low P/B ratio of 0.39 but negative revenue and net income margins. Recent earnings have consistently beaten expectations, and the company maintains regular dividend payments of $0.04 per share. Analyst sentiment is divided with 25% buy ratings, 55% hold, and 20% sell recommendations.
PSEC presents a high-risk, high-yield opportunity trading at a significant discount to book value. The investment case hinges on the company's ability to stabilize revenue and return to profitability while maintaining its dividend distribution. Key risks include persistent negative revenue trends, high leverage costs, and market skepticism about portfolio quality despite recent successful exits like the Valley Electric sale generating 4.8x returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
